Assistant Professor, Oncology, Mayo Medical School
Oncology
Dr. Timothy J. Hobday, MD
|
|
Give Review
Timothy Hobday practices Oncology. He went to Mayo Medical School. Mayo Medical School is ranked 27 in research and 42 in primary care medicine Timothy Hobday is a published doctor and has 37 publications published. The lastest was: 'Chronotropic response, safety, and accuracy of dobutamine stress echocardiography in patients with atrial fibrillation and known or suspected coronary artery disease.' Timothy J. Hobday is registered with Medicare.
Publications
- Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT...
- Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
- Risk factors for pancreatic Neuroendocrine tumors: a clinic-based case-control study.
- SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer.
- Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
- Regional differences in breast Cancer biomarkers in american Indian and alaska native women.
- Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast Cancer.
- Supplement use during an intergroup clinical trial for breast Cancer (S0221).
- Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.
- Treatment of neuroendocrine tumor Liver metastases.
- Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast Cancer patients enrolled in North Central Cancer Treatment Group (NCCT...
- Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-Gene Recurrence Score.
- Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast Cancer treatment trial (S0221).
- Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
- Daily oral everolimus activity in patients with metastatic pancreatic Neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
- Long-term survivors of metastatic coloRectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.
- Medical management of pancreatic Neuroendocrine tumors.
- Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid Tumors.
- A single-center experience with inflammatory breast Cancer, 1985-2003.
- Liver transplantation for gastroenteropancreatic neuroendocrine Cancers: Defining selection criteria to improve survival.
- Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine Carcinomas.
- Somatostatin Analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.
- An overview of approaches to adjuvant therapy for coloRectal cancer in the United States.
- Molecularly targeted therapies for breast Cancer.
- Imatinib mesylate-induced interstitial pneumonitis.
- Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic coloRectal carcinoma.
- Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced coloRectal cancer.
- Adjuvant therapy of colon Cancer: a review.
- Everolimus for advanced pancreatic Neuroendocrine tumors.
- Evaluation of metformin in early breast Cancer: a modification of the traditional paradigm for clinical testing of anti-Cancer agents.
- Chronotropic response, safety, and accuracy of dobutamine stress echocardiography in patients with atrial fibrillation and known or suspected coronary artery Disease.
- ColoRectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy.
- Can sorafenib cause hypothyroidism?
- Treatment of neuroendocrine Cancer metastatic to the liver: the role of ablative techniques.
- Characterization of the functional and growth properties of cell lines established from ileal and Rectal carcinoid tumors.
- Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic Neuroendocrine tumors.
Schools
Mayo Medical School
Mayo Grad School MedMayo Fndn
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
Education
-
Mayo School of Graduate Medical Education -
Mayo Medical School
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1316919962 | |
| NPPES Provider LastName | HOBDAY | |
| NPPES Provider FirstName | TIMOTHY | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 119.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316919962 |
| Last Name Of The Provider | HOBDAY |
| First Name Of The Provider | TIMOTHY |
| View All |
Similar Doctors
|
|
Dr. Janell N. Shaw, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith C. Bible, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jan C. Buckner, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Thomas E. Witzig, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. James A. Martenson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles L. Loprinzi, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Gary A. Croghan, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Patrick A. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul Haluska Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rattiya Cheewakriangkrai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arleigh B. Robertson McCurdy, MD |
|
|
Dr. Aditya Bardia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William R. Macon, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Kristin C. Francis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evanthia Galanis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Humeniuk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rakhee R. Vaidya, MD
This Doctor is OpenDoctor Recommended.
|